[Drugs under development for osteoporosis ].
Osteoporosis is a disease in which the density and quality of bone is reduced, leading to an increase in fragility fractures. Osteoporosis is a major health threat affecting more than 10 million people in Japan. Emerging evidence has shown that anti-resorptive drugs such as bisphosphonates and raloxifene efficiently increase bone mass and prevent osteoporotic fractures by maintaining bone homeostasis. In addition, anabolic drugs such as parathyroid hormone and novel anti-resorptive drugs such as anti-RANKL drugs and cathepsin K inhibitors, which directly target osteoclasts are under development. In this review, we would like to summarize the current status of the development of anti-osteoporotic drugs.
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo.
Hironari
H
Masuda
Sakae
S
Tanaka
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D056657:Cathepsin K; D002403:Cathepsins / Q000037:antagonists & inhibitors; D000069448:Denosumab; D004164:Diphosphonates; D015195:Drug Design; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles; D009942:Organometallic Compounds; D010024:Osteoporosis / Q000188:drug therapy*; D053244:Osteoprotegerin; D053245:RANK Ligand / Q000276:immunology; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide; D013876:Thiophenes
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D009942:Organometallic Compounds; D053244:Osteoprotegerin; D053245:RANK Ligand; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; C081587:strontium ranelate; D019379:Teriparatide; C087958:YM 529; D000069448:Denosumab; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K; D000077557:Ibandronic Acid